PMGC Holdings (ELAB) Work In Process (2023 - 2026)
PMGC Holdings' (ELAB) quarterly Work In Process came in at $325112.0 in Q2 2026, up 287.74% quarter-over-quarter from $83849.0 in Q1 2026.
Analysis
PMGC Holdings (ELAB) Work In Process (2023 - 2026) Analysis & Trends
PMGC Holdings has disclosed Work In Process across 3 years of filings, most recently posting $325112.0 for Q2 2026.
- In Q2 2026, Work In Process changed N/A year-over-year to $325112.0; the TTM figure through Jun 2026 stood at $325112.0 (changed N/A YoY), while the FY2023 annual figure was $147906.0, changed N/A from the prior year.
- Work In Process came in at $325112.0 for Q2 2026 at PMGC Holdings, up from $83849.0 in the prior quarter.
- In the past five years, Work In Process ranged from a high of $325112.0 in Q2 2026 to a low of $83849.0 in Q1 2026.
- Average Work In Process over 3 years is $236640.0, with a median of $286446.5 recorded in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.11 Bn | 193.12 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.91 Bn | 175.73 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.35 Bn | 123.50 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.06 Bn | 55.87 Bn | 1.37 Bn |
| 6 | Moderna | 53.08 Bn | 47.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.01 Bn | 992.69 Mn |
| 8 | Biogen | 31.70 Bn | 30.41 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.48 Bn | 29.48 Bn | 1.16 Mn |
| 10 | PMGC Holdings | 2.23 Mn | -16.56 Mn | 385,691.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 325,112.00 |
| Mar 31, 2026 | 83,849.00 |
| Sep 30, 2024 | 289,113.00 |
| Jun 30, 2024 | 290,080.00 |
| Mar 31, 2024 | 283,780.00 |
| Dec 31, 2023 | 147,906.00 |